Specificity of the ecto-ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases.

BACKGROUND AND PURPOSE: ARL 67156, 6-N,N-Diethyl-D-beta-gamma-dibromomethylene adenosine triphosphate, originally named FPL 67156, is the only commercially available inhibitor of ecto-ATPases. Since the first report on this molecule, various ectonucleotidases responsible for the hydrolysis of ATP at the cell surface have been cloned and characterized. In this work, we identified the ectonucleotidases inhibited by ARL 67156. EXPERIMENTAL APPROACH: The effect of ARL 67156 on recombinant NTPDase1, 2, 3 & 8 (mouse and human), NPP1, NPP3 and ecto-5'-nucleotidase (human) have been evaluated. The inhibition of the activity of NTPDases (using the following substrates: ATP, ADP, UTP), NPPs (pnp-TMP, Ap(3)A) and ecto-5'-nucleotidase (AMP) was measured by colorimetric or HPLC assays. KEY RESULTS: ARL 67156 was a weak competitive inhibitor of human NTPDase1, NTPDase3 and NPP1 with K(i) of 11+/-3, 18+/-4 and 12+/-3 microM, respectively. At concentrations used in the literature (50-100 microM), ARL 67156 partially but significantly inhibited the mouse and human forms of these enzymes. NTPDase2, NTPDase8, NPP3 and ecto-5'-nucleotidase activities were less affected. Importantly, ARL 67156 was not hydrolysed by either human NTPDase1, 2, 3, 8, NPP1 or NPP3. CONCLUSIONS AND IMPLICATIONS: In cell environments where NTPDase1, NTPDase3, NPP1 or mouse NTPDase8 are present, ARL 67156 would prolong the effect of endogenously released ATP on P2 receptors. However, it does not block any ectonucleotidases efficiently when high concentrations of substrates are present, such as in biochemical, pharmacological or P2X(7) assays. In addition, ARL 67156 is not an effective inhibitor of NTPDase2, human NTPDase8, NPP3 and ecto-5'-nucleotidase.

Triphasic expression of interleukin-1 receptor type I in human endometrium throughout the menstrual cycle of fertile women and women with unexplained infertility.

OBJECTIVE: To evaluate expression of interleukin-1 receptor type I in the endometrium of fertile women throughout the menstrual cycle and to investigate whether unexplained infertility may be associated with abnormal expression of IL-1 receptor type I. DESIGN: Retrospective study using immunohistochemical technique, Western blot assay, and reverse transcription polymerase chain reaction. SETTING: Gynecology clinic and human reproduction research laboratory. PATIENT(S): 39 fertile women and 25 women with unexplained infertility. INTERVENTION(S): Endometrial biopsy of samples obtained at laparoscopy. MAIN OUTCOME MEASURE(S): Immunostaining intensity, molecular weight, and messenger RNA levels of IL-1 receptor type I. RESULT(S): Immunostaining showed that two threshold days (13 and 22) separate the menstrual cycle into three distinct periods of IL-1 receptor type I expression, both in epithelial and stromal cells. Results of Western blot assay and reverse transcription polymerase chain reaction confirmed the immunohistochemical data. Statistical analyses showed that the pattern of IL-1 receptor type I expression was similar in women with unexplained infertility and fertile women. CONCLUSION(S): IL-1 receptor type I exhibits three distinct levels of expression throughout the menstrual cycle in the endometrium of fertile women, suggesting different physiologic roles of the receptor within the cycle. However, IL-1 receptor type I does not seem to be involved in unexplained infertility.

Comparative hydrolysis of P2 receptor agonists by NTPDases 1, 2, 3 and 8.

Nucleoside triphosphate diphosphohydrolases 1, 2, 3 and 8 (NTPDases 1, 2, 3 and 8) are the dominant ectonucleotidases and thereby expected to play important roles in nucleotide signaling. Distinct biochemical characteristics of individual NTPDases should allow them to regulate P2 receptor activation differentially. Therefore, the biochemical and kinetic properties of these enzymes were compared. NTPDases 1, 2, 3 and 8 efficiently hydrolyzed ATP and UTP with K (m) values in the micromolar range, indicating that they should terminate the effects exerted by these nucleotide agonists at P2X(1-7) and P2Y(2,4,11) receptors. Since NTPDase1 does not allow accumulation of ADP, it should terminate the activation of P2Y(1,12,13) receptors far more efficiently than the other NTPDases. In contrast, NTPDases 2, 3 and 8 are expected to promote the activation of ADP specific receptors, because in the presence of ATP they produce a sustained (NTPDase2) or transient (NTPDases 3 and 8) accumulation of ADP. Interestingly, all plasma membrane NTPDases dephosphorylate UTP with a significant accumulation of UDP, favoring P2Y(6) receptor activation. NTPDases differ in divalent cation and pH dependence, although all are active in the pH range of 7.0-8.5. Various NTPDases may also distinctly affect formation of extracellular adenosine and therefore adenosine receptor-mediated responses, since they generate different amounts of the substrate (AMP) and inhibitor (ADP) of ecto-5'-nucleotidase, the rate limiting enzyme in the production of adenosine. Taken together, these data indicate that plasma membrane NTPDases hydrolyze nucleotides in a distinctive manner and may therefore differentially regulate P2 and adenosine receptor signaling.

Interleukin-1 receptor accessory protein is constitutively expressed in human endometrium throughout the menstrual cycle.

Interleukin-1 (IL-1) is one of the principal cytokines that participate in endocrine and local regulation of many endometrial and reproductive functions. The cellular response to IL-1 principally implicates receptor type 1 (IL-1R tI) and, according to recent data, an accessory protein (IL-1R-AcP) that seems to play an essential function in signal transduction. In the present study, we examined the expression of IL-1R-AcP in the endometrium of 39 normal fertile women throughout the menstrual cycle. As studied by immunohistochemistry, IL-1R-AcP was detected across endometrial tissue, but more noticeably in the glands and luminal epithelium. The intensity of IL-1R-AcP immunostaining was consistently high throughout the menstrual cycle, and this was confirmed by Western blot analysis of the protein and corroborated by reverse transcription-polymerase chain reaction analysis of the mRNA. To our knowledge, this is the first report showing that IL-1R-AcP is expressed in endometrial tissue, and without any noticeable variation throughout the menstrual cycle. This suggests that the accessory protein, whose co-expression is critical for IL-1R tI-mediated cell activation, is, in contrast to the functional receptor, constitutively expressed and not subject to similar cycle-dependent regulation.